Promomed's revenue in 2025 increased by 75%

Promomed's revenue by the end of 2025 amounted to ₽38 billion, an increase of 75.2%, which is 6 times higher than the growth rate of the pharmaceutical market, which amounted to 11.6% according to IQVIA. In the Endocrinology segment, revenue increased 2.6 times and amounted to ₽21.6 billion. In the Oncology segment, sales increased by 43% to ₽7 billion. The shares of budget and commercial sales in revenue amounted to 34% and 66%, respectively. In the budget channel, sales increased by 26%, in the commercial channel — by 2.2 times.